Drug Patents owned by Myovant Sciences
1. Drug name - MYFEMBREE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(1 year, 4 months from now) | |
| US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(1 year, 4 months from now) | |
| CN101153042A | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Sep, 2011
(11 years ago) | |
| CN100360538C | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| CN1768065A | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| IN200501636P2 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| IN235678B | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| EP1591446A4 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| EP1591446A1 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| EP1591446B1 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9346822 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 4 months from now) | |
| US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(15 years from now) | |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG;0.5MG;40MG | TABLET;ORAL | Prescription |
2. Drug name - ORGOVYX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(1 year, 4 months from now) | |
| US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(1 year, 4 months from now) | |
| CN101153042A | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Sep, 2011
(11 years ago) | |
| CN100360538C | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| CN1768065A | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| IN200501636P2 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| IN235678B | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| EP1591446A4 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| EP1591446A1 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| EP1591446B1 | MYOVANT SCIENCES | Thienopyrimidine Compounds And Use Thereof |
Jan, 2024
(1 year, 4 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735401 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 4 months from now) | |
| US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(13 years from now) | |
| US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(15 years from now) | |
| US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(15 years from now) | |
Drugs and Companies using RELUGOLIX ingredient
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 120MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.